Abstract: The present invention relates to a novel coronavirus recombinant spike protein, a polynucleotide encoding the same, a vector comprising the polynucleotide, and a vaccine for preventing or treating coronavirus infection, comprising the vector. The coronavirus recombinant spike protein of the present invention is stable and thereby not easily decomposed in cells, and effectively activates immune cells thereby resulting in a high antibody production amount and T cell reactivity. It was confirmed that the vector of the present invention exhibits a high antigen expression level and thereby has a high antibody production amount and T cell reactivity, has a long antibody production period and expression period, and does not show liver toxicity. Accordingly, the vector of the present invention can be helpfully used as a vaccine for preventing or treating coronavirus infection.

Abstract: The present invention relates to an immunoprophylactic and therapeutic vaccine comprising peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen, and specifically, to an immunotherapeutic vaccine comprising peripheral blood mononuclear cells loaded with alpha-galactosylceramide, a natural killer T cell ligand and a type of glycolipid. A composition of the present invention is easy to obtain because there is no need to separate specific cells from peripheral blood mononuclear cells. In addition, immunization of peripheral blood mononuclear cells loaded with a natural killer T cell ligand and an antigen not only induces significant levels of activation of natural killer cells and natural killer T cells and cytotoxic T lymphocyte responses, but also has a synergistic effect in the treatment of malignant tumors and thus can be helpfully used as an anticancer immunotherapeutic agent.

Abstract: The present invention relates to a novel adenoviral vector not including a replication competent adenovirus. A recombinant E1/E3/E4-deleted adenoviral vector, of the present invention, in which an antigenic protein and an E4orf6 gene are inserted in an E1 gene-deleted region, has adenovirus productivity, degree of antigen expression, neutralizing antibody production amount, and T cell induction ability that are similar to those of a control group, and thus can be effectively used as a carrier for various vaccines for diseases or anti-cancer vaccines.

Abstract: The present invention relates to a novel adenoviral vector not including a replication competent adenovirus. A recombinant E1/E3/E4-deleted adenoviral vector, of the present invention, in which an antigenic protein and an E4orf6 gene are inserted in an E1 gene-deleted region, has adenovirus productivity, degree of antigen expression, neutralizing antibody production amount, and T cell induction ability that are similar to those of a control group, and thus can be effectively used as a carrier for various vaccines for diseases or anti-cancer vaccines.

Abstract: The present invention relates to an immuno-therapeutic and prophylactic vaccine comprising monocytes or immature myeloid cells (IMCs) loaded with the ligand of natural killer T cell and an antigen for the prevention and treatment of infectious disease or cancer, more precisely, an immuno-therapeutic and prophylactic vaccine comprising monocytes or IMCs loaded with ?-galactosylceramide (?GalCer), a kind of glycolipid and a natural killer T cell ligand, and antigen. Monocytes or immature myeloid cells (IMCs) therein, which are easily obtainable, unlike dendritic cells, not only induce a significant level of cytotoxic T lymphocyte responses but also have a prophylactic and therapeutic effect on malignant tumor. Therefore, the immuno-therapeutic and prophylactic vaccine of the present invention can be effectively used as an immunotherapeutic agent.